PLAUR and COVID-19: These findings position uPAR as a potential biomarker for fibrotic progression and a candidate target for antifibrotic therapies, not only in COVID-19 but also in idiopathic pulmonary fibrosis (IPF) and post-viral fibrotic syndromes.